Study of selinexor, bortezomib, and dexamethasone for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with active multiple myeloma
- Your myeloma has returned after 1 to 3 previous treatments
- You have already taken at least one dose of selinexor, bortezomib, and dexamethasone as part of this study (in Italy)
- You have been treated with lenalidomide before and it stopped working
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This study tests a new combination of drugs for people with multiple myeloma that has stopped responding to previous treatments. The goal is to see if adding selinexor to other anti-myeloma drugs can help control the disease.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
This trial tests a medicine called SIL as a maintenance treatment for multiple myeloma. You take it after a stem cell transplant to help keep the cancer from coming back.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.